I-Mab continues trend of large Chinese-led venture rounds

I-Mab Biopharma (Shanghai, China) raised $220 million Friday in a series C round led by Hony Capital, making it at least the fourth $200 million-plus VC round led by Chinese investors in the past two months.

Also participating in I-Mab’s round were Hillhouse Capital, HOPU Investments, CDH Investment, Ally Bridge Group and EDBI alongside existing investors C-Bridge Capital and Tasly Capital. Hony's parent company is investment firm Legend Holdings Corp. (HKSE:3396)...